Focus on Lipids Care

Back to articles

Niacin: New data may be final nail in the coffin

KEY POINT

The addition of niacin–laropiprant to statin-based therapy in patients with known vascular disease did not reduce the risk of major vascular events and was associated with an increased risk of serious adverse events, according to results of the the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2–THRIVE) study published in a recent issue of The New England Journal of Medicine.  

SOURCES

The HPS2–THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.

Lloyd-Jones DM. Niacin and HDL cholesterol—time to face facts [editorial]. N Engl J Med. 2014;371:271–273. 

Anderson TJ et al. Safety profile of extended-release niacin in the AIM–HIGH trial. N Engl J Med. 2014;371:288–290.